Milliman
Gene Therapy Access Gaps for Sickle Cell Disease Carry Big Medicaid Implications
Milliman examines barriers limiting patient access to new sickle cell disease (SCD) cell and gene therapies, including treatment center geography, hospital capacity, long lead times, and ancillary services like fertility preservation. Because SCD disproportionately affects Medicaid beneficiaries, the paper's recommendations on improving insurance coverage design are relevant for Medicaid managed care plans grappling with high-cost specialty drug coverage and network adequacy for rare disease treatment.
This is outside commentary from Milliman, not part of Medicaid Monitor's independently scored news coverage.